Elvina Almuradova/X
Sep 17, 2024, 14:27
Elvina Almuradova: Promising results from the NO-CUT trial in pMMR LARC patients
Elvina Almuradova, Associate Professor, Medicana Health Group,
“Promising results from the NO-CUT trial (TNT with a nonoperative approach) in pMMR LARC patients:
- Distant Relapse-Free Survival (DRFS30)**: 96.9% in the NOM cohort vs. 74% in the ReSU cohort
- Local regrowth**: 15% in NOM vs. 9% in ReSU
- Deaths**: 12 deaths (6.6%), including 1 AE-related and 9 tumor-related
- Circulating tumor DNA**: Correlated with cCR and DRFS in the first 77 patients.”
Source: Elvina Almuradova/LinkedIn
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Feb 21, 2025, 13:07
Feb 21, 2025, 13:06
Feb 21, 2025, 13:03
Feb 21, 2025, 13:00
Feb 21, 2025, 12:53
Feb 21, 2025, 12:41
Feb 21, 2025, 12:39